Financial Performance - The company achieved operating revenue of ¥1,446,581,643.36, an increase of 85.40% compared to the same period last year[4] - The total profit reached ¥859,489,481.62, reflecting a growth of 144.93% year-over-year[4] - Net profit attributable to shareholders was ¥733,461,178.85, up 144.65% from the previous year[4] - The basic earnings per share increased to ¥8.29, representing a growth of 132.21% year-over-year[4] Assets and Equity - Total assets at the end of the reporting period were ¥2,064,166,266.85, a 43.89% increase from the beginning of the period[4] - Shareholders' equity attributable to the company increased to ¥1,537,467,511.57, up 61.22% from the start of the period[4] Business Development - The company actively developed new products and strengthened brand building, contributing to sustainable revenue growth[5] - The increase in revenue was primarily driven by significant growth in sales of medical devices and functional skincare products[6] - The company experienced improved profit margins due to steady revenue growth and scale effects[6] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, which may differ from the final report[8]
锦波生物(832982) - 2024 Q4 - 年度业绩